The use of opiate antagonists in treating bulimia: A study of low-dose versus high-dose naltrexone

Psychiatry Research

Volumn 24, Issue 2, 1988, Pages 195-199

  Jonas, Jeffrey M ^a   Gold, Mark S ^a,b  

^a Psychiatric Diagnostic Laboratories of America   (United States)

^b Mark S Gold MD is Director of Research Facilities Fair Oaks Hospital Summit NJ USA ^*  (United States)

Author keywords

autoaddiction; Bulimia; endorphins; naltrexone

Indexed keywords

NALTREXONE;

ADULT; BULIMIA; CLINICAL ARTICLE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

BULIMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; NALTREXONE; RECEPTORS, OPIOID;

EID: 0023910670     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/0165-1781(88)90062-5     Document Type: Article

References (12)

1. Plasma immunoreactive betaendorphin in bulimics
2. A rating scale for depression
3. Naltrexone reverses bulimic symptoms
4. Treatment of antidepressant-resistant bulimia with naltrexone
5. The role of opioid peptides in feeding regulation
6. Naloxone but not CCK-8 may attenuate binge-eating behavior in patients with the bulimia syndrome
7. High-dose naltrexone therapy and dietary counseling for obesity
8. An investigation of the role of kappa opiate receptor agonists in the initiation of feeding
9. Trexan (naltrexone hydrochloride): A review of hepatic toxicity at high dosage
10. Plasma beta-endorphin in binge eating and bulimia
11. Eating behavior and plasma beta-endorphin in bulimia